| 17.53 0.67 (3.97%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.4 |
1-year : | 26.16 |
| Resists | First : | 19.18 |
Second : | 22.4 |
| Pivot price | 16.68 |
|||
| Supports | First : | 16.49 |
Second : | 14.84 |
| MAs | MA(5) : | 17.07 |
MA(20) : | 16.88  |
| MA(100) : | 16.83 |
MA(250) : | 16.54 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 63.5 |
D(3) : | 59.3 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 24.5 | Low : | 8.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLFS ] has closed below upper band by 23.4%. Bollinger Bands are 27.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.57 - 17.64 | 17.64 - 17.7 |
| Low: | 16.42 - 16.5 | 16.5 - 16.57 |
| Close: | 17.38 - 17.52 | 17.52 - 17.64 |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Fri, 19 Apr 2024
Further weakness as BioLife Solutions (NASDAQ:BLFS) drops 7.3% this week, taking three-year losses to 52% - Simply Wall St
Thu, 18 Apr 2024
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business - PR Newswire
Tue, 16 Apr 2024
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Up 5.6% in March - MarketBeat
Thu, 04 Apr 2024
Market Sentiment Around Loss-Making BioLife Solutions, Inc. (NASDAQ:BLFS) - Simply Wall St
Fri, 29 Mar 2024
Investors in BioLife Solutions (NASDAQ:BLFS) have unfortunately lost 49% over the last three years - Yahoo Finance
Thu, 14 Mar 2024
Director Amy Duross Sells 11200 Shares of BioLife Solutions Inc (BLFS) Director Amy Duross Sells 11200 Shares of ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 45 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 102.4 (%) |
| Shares Short | 3,200 (K) |
| Shares Short P.Month | 3,280 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.48 |
| Profit Margin | -46.4 % |
| Operating Margin | -41.5 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -19 % |
| Qtrly Rev. Growth | -26 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.16 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -11.54 |
| PEG Ratio | -1.6 |
| Price to Book value | 2.34 |
| Price to Sales | 5.54 |
| Price to Cash Flow | -63.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|